Effects of Xuefu Zhuyu oral liquid as adjunctive treatment for stable angina: a randomized controlled trial
Frontiers in Medicine · 29.04.2026 · 13
DOI: 10.3389/fmed.2026.1787481 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Medicine, online erschienen am 29.04.2026. Verfasst von Wencong Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Stable angina (SA) remains a major cause of global disability. Xuefu Zhuyu oral liquid (XZOL), a traditional Chinese medicine, is used for SA in China, but rigorous evidence of its efficacy is lacking. We aimed to evaluate the efficacy and safety of XZOL as an adjunctive therapy for patients with SA.
Methods
We conducted a multicenter, randomized, double-blind, placebo-controlled trial across six hospitals in China. Between June 2020 and June 2022, eligible patients with SA were randomly assigned (1:1) to receive either XZOL or a matching placebo for 12 weeks, in addition to standard antianginal therapy. All participants were followed for an additional 12 weeks. The primary outcome was the change in average angina pain intensity from baseline to week 12, measured on a 10-cm visual analog scale (VAS).
Results
Of 263 patients screened, 148 were included in the full analysis set (74 per group). At week 12, patients receiving XZOL showed a reduction in VAS pain scores compared to placebo (adjusted mean difference, –0.63; 95% CI, –1.12 to –0.14; P = 0.012). This effect was sustained at the 24-week follow-up (–0.47; 95% CI, –0.94 to –0.002; P = 0.049). Furthermore, the XZOL group had significantly lower use of rescue nitroglycerin at both week 12 (2.7% vs. 13.5%; P = 0.016) and week 24 (2.7% vs. 12.2%; P = 0.029). Adverse events were comparable between groups.
Conclusion
Adjunctive treatment with XZOL for 12 weeks significantly reduced angina pain intensity and the need for rescue medication in patients with stable angina, with a favorable safety profile. Clinical trial registration https://clinicaltrials.gov/ , ChiCTR1900026899.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
- Vincent V.C. Woo Chinese Medicine Clinical Research Institute, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China.
- Chinese EQUATOR Centre, Kowloon, Hong Kong SAR, China.
- Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
- Center for Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China.
- Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, Guangdong, China.
Zitieren
APA
Cao, W., Liao, S., Zhou, L., Li, G., Jiang, J., Lv, W., Dong, B., Liu, L., Zhang, J., Wang, Y., Ouyang, W., Du, Y., & Wen, Z. (2026). Effects of Xuefu Zhuyu oral liquid as adjunctive treatment for stable angina: a randomized controlled trial. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1787481
Vancouver
Cao W, Liao S, Zhou L, Li G, Jiang J, Lv W, et al. Effects of Xuefu Zhuyu oral liquid as adjunctive treatment for stable angina: a randomized controlled trial. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1787481
BibTeX
@article{Cao2026,
author = {Cao, Wencong and Liao, Shaojun and Zhou, Li and Li, Geng and Jiang, Junwen and Lv, Weihui and Dong, Bo and Liu, Li and Zhang, Jie and Wang, Yanchun and Ouyang, Wenwei and Du, Yi and Wen, Zehuai},
title = {Effects of Xuefu Zhuyu oral liquid as adjunctive treatment for stable angina: a randomized controlled trial},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1787481}
}
EUVIMED